专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019023579A1 METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS 审中-公开
公开(公告)号：WO2019023579A1
公开(公告)日：2019-01-31
申请号：PCT/US2018/044094
申请日：2018-07-27
申请人： THE MCLEAN HOSPITAL CORPORATION
发明人： KIM, Kwang-Soo , JANG, Yongwoo , KIM, Chun-Hyung
IPC分类号： A61K31/216 , A61K31/235 , A61K31/404
CPC分类号： A61K31/5575 , A61K31/4706 , A61K31/558 , A61K38/177 , A61K2300/00
摘要： Provided herein are methods and compositions for treating a Nurr1-mediated and/or PPAR- mediated condition. Also provided herein are methods and compositions for increasing Nurr1 or PPAR activity and/or levels in a cell.

2. 发明申请

WO2017119988A2 RADIOPROTECTION BY WNT ACTIVATION 审中-公开
标题翻译： WNT激活的放射性防护
公开(公告)号：WO2017119988A2
公开(公告)日：2017-07-13
申请号：PCT/US2016/065912
申请日：2016-12-09
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： LOWE, Scott W. , ROMESSER, Paul B. , DOW, Lukas
CPC分类号： A61K31/5575 , A61K31/65 , A61K31/7105 , A61K45/06 , A61K2300/00
摘要： The present invention encompasses the recognition that a multipotent actively cycling intestinal stem cell population exists in the bottom of intestinal crypts and is highly sensitive to irradiation. In some embodiments, the present invention recognizes that proliferation of stem cells in the gut after exposure of a subject to radiation can be beneficial to the subject.
摘要翻译：本发明包括认识到多能活性循环肠干细胞群存在于肠隐窝的底部并且对辐射高度敏感。在一些实施方案中，本发明认识到受试者暴露于辐射后肠道中干细胞的增殖可能有益于受试者。

3. 发明申请

WO2017019773A1 SUSTAINED-RELEASE DRUG FORMULATIONS FOR GLAUCOMA 审中-公开
标题翻译：持续发布GLAUCOMA的药物配方
公开(公告)号：WO2017019773A1
公开(公告)日：2017-02-02
申请号：PCT/US2016/044271
申请日：2016-07-27
申请人： LAYERBIO, INC. , WHITE, Aleksandr
发明人： WHITE, Aleksandr , MANDELL, Kenneth
IPC分类号： A61K38/14 , A61K47/48
CPC分类号： A61K47/48315 , A61K9/0048 , A61K31/5575 , A61K47/645 , C08G69/10 , C08G69/48
摘要： A polymer-drug conjugate includes a crosslinked polymer network comprising a biocompatible polymer and a multivalent covalent crosslinker, wherein the multivalent crosslinker comprises an active ingredient precursor covalently bonded through two or more bonds to the biocompatible polymer, and wherein the covalent bond is a hydrolysable bond. The drug can be for treatment of glaucoma and the free drug is biologically active and selected to lower eye pressure.
摘要翻译：聚合物 - 药物缀合物包括包含生物相容性聚合物和多价共价交联剂的交联聚合物网络，其中所述多价交联剂包含通过两个或更多个键共价键合到所述生物相容性聚合物的活性成分前体，并且其中所述共价键是可水解键。该药物可用于治疗青光眼，并且游离药物具有生物活性并被选择以降低眼压。

4. 发明申请

WO2016097297A1 DRUG DELIVERY SYSTEM FOR DELIVERY OF ACID SENSITIVE DRUGS 审中-公开
标题翻译：用于输送感冒药物的药物递送系统
公开(公告)号：WO2016097297A1
公开(公告)日：2016-06-23
申请号：PCT/EP2015/080503
申请日：2015-12-18
申请人： DSM IP ASSETS B.V.
发明人： MIHOV, George , DRAAISMA, Guy , SILVESTRE, DI, Silvana Rensina Antonnietta , HANDELS, Tristan
IPC分类号： A61K9/70 , A61K47/34 , A61K31/5575 , C08G69/44 , C08L77/00 , A61P27/06 , A61P27/02
CPC分类号： A61K9/70 , A61F9/0008 , A61F9/0017 , A61F9/00781 , A61F2009/00872 , A61F2009/00891 , A61K9/0051 , A61K31/5575 , A61K47/34 , C08G69/36 , C08G69/44 , C08L77/12
摘要： The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.
摘要翻译：本发明涉及药物递送系统，其包括核心和壳体，其中核心包含水解可降解聚合物X，该聚合物主链包含侧酯和酸官能团，并且其中壳包含水解可降解聚合物Y.水解可降解聚合物 X和Y是不同的聚合物。聚合物X还包含聚合物主链中的氨基酸，并通过零级降解动力学降解至少3个月的时间。聚合物Y通过自动加速降解动力学降解。

5. 发明申请

WO2016063184A1 OPHTHALMIC SOLUTION 审中-公开
标题翻译： OPHTHALMIC解决方案
公开(公告)号：WO2016063184A1
公开(公告)日：2016-04-28
申请号：PCT/IB2015/057963
申请日：2015-10-16
申请人： SENTISS PHARMA PRIVATE LIMITED
发明人： SHAH, Mandar V. , BAHRI, Deepak
IPC分类号： A61K45/06 , A61K31/5377 , A61K31/542 , A61K31/5575 , A61K9/00 , A61K47/32 , A61K47/34 , A61P27/06
CPC分类号： A61K31/5575 , A61K9/0048 , A61K31/5377 , A61K31/542 , A61K45/06 , A61K47/26 , A61K47/34 , A61K2300/00
摘要： Disclosed herein an ophthalmic formulation comprises carbonic anhydrase inhibitor(s) alone, in an aqueous solution or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents and a manufacturing process thereof. The present invention further relates to the composition(s) manufactured by the process described herein and methods for treating persons suffering from glaucoma or ocular hypertension. In particular, the persons are treated with carbonic anhydrase inhibitor(s) alone or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents to control their intraocular pressure (IOP). Further disclosed herein the formulations as manufactured relate to a highly solubilized form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.
摘要翻译：本文公开的眼用制剂包含单独的碳酸酐酶抑制剂，在水溶液中或两种眼内压（IOP）还原和/或青光眼治疗剂的组合或三种眼内压（IOP）还原和/或青光眼的组合处理剂及其制造方法。本发明还涉及通过本文所述方法制造的组合物和治疗患有青光眼或高眼压症的人的方法。特别地，这些人单独使用碳酸酐酶抑制剂或两种眼内压（IOP）还原和/或青光眼治疗剂或三种眼内压（IOP）还原和/或青光眼治疗剂的组合的组合治疗至控制其眼内压（IOP）。本文进一步公开，制造的制剂涉及高度溶解形式的不良溶解性药物/活性成分，以改善其生物利用度和可制造性。

6. 发明申请

WO2016061370A1 PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION 审中-公开
标题翻译： PROSTAGLANDIN结合物和治疗GLAUCOMA和OCULAR HYPERTENSION的衍生物
公开(公告)号：WO2016061370A1
公开(公告)日：2016-04-21
申请号：PCT/US2015/055766
申请日：2015-10-15
申请人： NOVARTIS AG , ELLIS, David , SCHEIBLER, Lukas , SHARIF, Najam
发明人： ELLIS, David , SCHEIBLER, Lukas , SHARIF, Najam
IPC分类号： A61K31/5575 , A61P27/06
CPC分类号： A61K31/5575 , A61K9/0048 , A61K9/08 , A61K31/559 , A61K45/06 , C07C205/49 , C07D295/28 , A61K2300/00
摘要： Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention.
摘要翻译：公开前列腺素缀合物及其用于治疗青光眼和/或降低眼内压的衍生物和方法。另外，公开了可用于治疗眼睛疾病如青光眼和升高的眼内压的眼用药物组合物。这样的组合物包含有效量的本发明的前列腺素缀合物或衍生物。

7. 发明申请

WO2016044902A1 PHARMACEUTICAL COMPOSITION OF 15-DEOXY-DELTA-12,14-PROSTAGLANDIN J2 IN A POLOXAMER-BASED MICELLAR SYSTEM AND ITS USE FOR TREATMENT OF INFLAMMATORY CONDITIONS 审中-公开
标题翻译：基于聚氧乙烯的麦芽糖系统中15-去氧-D-12,14-PROSTAGLANDIN J2的药物组合物及其用于治疗炎症病症的用途
公开(公告)号：WO2016044902A1
公开(公告)日：2016-03-31
申请号：PCT/BR2014/000349
申请日：2014-09-26
申请人： SOCIEDADE REGIONAL DE ENSINO E SAÚDE SS LTDA , UNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP , FUNDAÇÃO UNIVERSIDADE FEDERAL DO ABC , UNIVERSIDADE ESTADUAL PAULISTA JÚLIO DE MESQUITA FILHO - UNESP , CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA.
发明人： NAPIMOGA, Marcelo Henrique , NAPIMOGA, Juliana Trindade Clemente , ARAUJO, Daniele Ribeiro de , FRACETO, Leonardo Fernandes
IPC分类号： A61K31/5575 , A61K9/10 , A61K9/14 , A61K9/66 , A61K47/34
CPC分类号： A61K9/1075 , A61K9/0019 , A61K31/5575 , A61K47/10
摘要： The present invention is related to a pharmaceutical composition comprising a poloxamer-based micellar system, 15-deoxy-Δ-12,14-prostaglandin J2 as the active ingredient and an aqueous carrier, with prolonged residence time at the site of injection, inducing potent and sustained analgesic and anti-inflammatory effect, being particularly useful for treatment of inflammatory conditions of joints and arthritis.
摘要翻译：本发明涉及一种药物组合物，其包含基于泊洛沙姆的胶束体系，15-脱氧-Δ-12,14-前列腺素J2作为活性成分和水性载体，在注射部位具有延长的停留时间，诱导有效并具有持续的止痛和抗炎作用，特别适用于治疗关节和关节炎的炎症状态。

8. 发明申请

WO2015197562A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OR DISEASES ASSOCIATED WITH RYANODINE RECEPTOR DYSFUNCTION 审中-公开
标题翻译：用于治疗与雷诺孕素受体功能相关的疾病或疾病的方法和药物组合物
公开(公告)号：WO2015197562A1
公开(公告)日：2015-12-30
申请号：PCT/EP2015/064002
申请日：2015-06-22
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE MONTPELLIER , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
发明人： LACAMPAGNE, Alain , LE GUENNEC, Jean-Yves , BULTEL-PONCE, Valérie , GALANO, Jean-Marie , GUY, Alexandre , DURAND, Thierry , OGER, Camille , MATECKI, Stefan , DRIDI, Haikel , THIREAU, Jérôme , ROY, Jérôme
IPC分类号： A61K31/5575 , A61P9/00 , A61P3/10 , A61P11/00 , A61P43/00
CPC分类号： A61K31/5575
摘要： The present invention relates to method and pharmaceutical composition for the treatment of disorders or diseases associated with Ryanodine Receptor (RyR) dysfunction. In particular, the present invention relates to a method of treating a disease associated with a RyR dysfunction in a subject in need thereof comprising administering the subject with a therapeutically effective amount of F4-neuroprostane (F4-NeuroP).
摘要翻译：本发明涉及用于治疗与兰诺定受体（RyR）功能障碍相关的疾病或疾病的方法和药物组合物。特别地，本发明涉及治疗有需要的受试者的与RyR功能障碍有关的疾病的方法，包括给予受试者治疗有效量的F4-神经丝氨酸（F4-NeuroP）。

9. 发明申请

WO2015195894A1 METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS 审中-公开
标题翻译：用于调节内啡肽水平的方法和组合物
公开(公告)号：WO2015195894A1
公开(公告)日：2015-12-23
申请号：PCT/US2015/036399
申请日：2015-06-18
申请人： THE GENERAL HOSPITAL CORPORATION
发明人： FISHER, David E. , ROBINSON, Kathleen , FELL, Gillian , VEGUILLA, Rosa
IPC分类号： A61K38/00
CPC分类号： A61K31/352 , A61K9/0014 , A61K31/137 , A61K31/167 , A61K31/222 , A61K31/4015 , A61K31/444 , A61K31/4709 , A61K31/522 , A61K31/5575 , A61K31/573 , A61K38/043 , A61K38/046 , A61K38/164 , A61K38/2228 , A61K38/2271 , A61K38/29 , A61K38/33 , A61N5/0616 , A61N2005/0661 , Y02A50/471
摘要： Methods and compositions for treatment of pain, mood, or for the treatment of opiate withdrawal symptoms with the modulation of systemic beta-endorphin levels by the topical administration of cAMP elevating agents and/or dermal exposure to ultraviolet (UV) irradiation.
摘要翻译：用于通过局部施用cAMP升高剂和/或经皮暴露于紫外（UV）照射来调节全身β-内啡肽水平来治疗疼痛，情绪或用于治疗阿片戒断症状的方法和组合物。

10. 发明申请

WO2015179527A1 TOPICAL FORMULATIONS AND USES THEREOF 审中-公开
标题翻译：主题制作及其用途
公开(公告)号：WO2015179527A1
公开(公告)日：2015-11-26
申请号：PCT/US2015/031788
申请日：2015-05-20
申请人： WEISS, Sidney L. , OCULAR TECHNOLOGIES SARL
发明人： WEISS, Sidney L.
IPC分类号： A61K47/44 , A61K47/10 , A61K9/127 , A61K31/4164 , A61K31/498 , A61K31/542 , A61P27/02
CPC分类号： A61K31/5575 , A61K9/0048 , A61K9/08 , A61K9/1075 , A61K31/498 , A61K31/506 , A61K31/542 , A61K47/10 , A61K47/44
摘要： Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
摘要翻译：本文提供了用于局部给药的制剂，例如眼用制剂，以及使用这些制剂的方法。在一些方面和实施方案中，制剂可以包括聚氧脂质或脂肪酸，和/或聚烷氧基化的醇，并且可以包括纳米胶束。还包括治疗或预防诸如眼部疾病或病症的疾病或病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式